Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

6.8K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Landscape of Prostate Tumour Methylation.

Cancer discovery·2026
Same author

Moderate hypofractionated boost to the prostate with pelvic radiotherapy in high-risk prostate cancer (MOB-RT) - a phase 2 study: acute safety and quality of life outcomes.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same author

A practical framework for operationalising responsible and equitable artificial intelligence in health care: tackling bias, inequity, and implementation challenges.

The Lancet. Digital health·2026
Same author

Downregulation of ANPEP Is Associated with Aggressive Prostate Cancer and Poor Disease-specific Outcomes.

European urology open science·2026
Same author

Real-Time Magnetic Resonance Imaging Guidance to Enable Brachytherapy: A Case Series.

Practical radiation oncology·2026
Same author

Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancer.

Nature communications·2025

Related Experiment Video

Updated: Nov 5, 2025

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
06:08

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

560

Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer.

Rebecca G Philipson1, Tahmineh Romero2, Jessica K Wong3

  • 1Department of Radiation Oncology, University of California Los Angeles, Los Angeles, CA, USA.

European Urology
|May 14, 2021
PubMed
Summary

High-risk prostate cancer recurring after radiation therapy is aggressive, with 50% developing distant metastases within 5 years after external beam radiation therapy. Early detection of metastases after biochemical recurrence is crucial for managing this aggressive disease.

Keywords:
Biochemical recurrenceBrachytherapy boostEBRTExternal beam radiation therapyHigh-risk prostate cancerProstate cancerRadiorecurrenceRecurrent prostate cancer

More Related Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.0K
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.8K

Related Experiment Videos

Last Updated: Nov 5, 2025

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
06:08

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

560
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.0K
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.8K

Area of Science:

  • Urology
  • Radiation Oncology
  • Medical Oncology

Background:

  • The natural history of radiorecurrent high-risk prostate cancer (HRPCa) is not well-characterized.
  • Understanding disease progression post-radiation is crucial for guiding treatment strategies.

Purpose of the Study:

  • To evaluate the rates of distant metastases (DM) and prostate cancer-specific mortality (PCSM) in patients with radiorecurrent HRPCa.
  • To analyze the clinical course and outcomes in a large cohort of men treated with different radiation modalities.

Main Methods:

  • Retrospective cohort study of 978 men with radiorecurrent HRPCa from 1997-2015.
  • Patients received either external beam radiation therapy (EBRT) or EBRT plus brachytherapy (EBRT+BT).
  • Analysis of DM and PCSM rates, with median follow-up of 8.9 years post-treatment and 3.7 years post-biochemical recurrence (BCR).

Main Results:

  • 5-year DM rates were 50% after EBRT and 34% after EBRT+BT, measured from recurrence.
  • 5-year PCSM rates were 27% after EBRT and 29% after EBRT+BT, measured from BCR.
  • A significant proportion of DM (248/435) were detected within 1 year of BCR; interval to BCR independently predicted DM and PCSM.

Conclusions:

  • Radiorecurrent HRPCa exhibits an aggressive natural history with a high risk of early distant metastases.
  • Distant metastases are often clinically evident within the first year of biochemical recurrence.
  • These findings highlight the need for improved upfront risk stratification and prompt systemic evaluation upon recurrence in HRPCa.